A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 07 Sep 2022 Status changed from active, no longer recruiting to completed.
- 02 Jun 2022 Planned End Date changed from 15 Nov 2022 to 28 Jul 2022.
- 02 Jun 2022 Planned primary completion date changed from 15 Aug 2022 to 28 Jul 2022.